HRP20240585T1 - Postupci uzgoja stanica - Google Patents
Postupci uzgoja stanica Download PDFInfo
- Publication number
- HRP20240585T1 HRP20240585T1 HRP20240585TT HRP20240585T HRP20240585T1 HR P20240585 T1 HRP20240585 T1 HR P20240585T1 HR P20240585T T HRP20240585T T HR P20240585TT HR P20240585 T HRP20240585 T HR P20240585T HR P20240585 T1 HRP20240585 T1 HR P20240585T1
- Authority
- HR
- Croatia
- Prior art keywords
- recombinant protein
- total amount
- seq
- production phase
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2511/00—Cells for large scale production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1708655.4A GB201708655D0 (en) | 2017-05-31 | 2017-05-31 | Cell culture methods |
| PCT/EP2018/064102 WO2018219968A1 (en) | 2017-05-31 | 2018-05-29 | Cell culture methods |
| EP18743683.7A EP3630946B1 (en) | 2017-05-31 | 2018-05-29 | Cell culture methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240585T1 true HRP20240585T1 (hr) | 2024-07-19 |
Family
ID=59270991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240585TT HRP20240585T1 (hr) | 2017-05-31 | 2018-05-29 | Postupci uzgoja stanica |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US12077796B2 (https=) |
| EP (2) | EP4397682A3 (https=) |
| JP (3) | JP7460370B2 (https=) |
| KR (3) | KR20240096888A (https=) |
| CN (2) | CN110741077B (https=) |
| AU (2) | AU2018276376C1 (https=) |
| BR (1) | BR112019024390A2 (https=) |
| CA (1) | CA3065661A1 (https=) |
| CL (1) | CL2019003459A1 (https=) |
| CO (1) | CO2019012871A2 (https=) |
| EA (1) | EA201992828A1 (https=) |
| ES (1) | ES2978394T3 (https=) |
| GB (1) | GB201708655D0 (https=) |
| HR (1) | HRP20240585T1 (https=) |
| HU (1) | HUE066922T2 (https=) |
| IL (2) | IL270880B2 (https=) |
| MX (1) | MX2019014140A (https=) |
| MY (1) | MY193535A (https=) |
| PL (1) | PL3630946T3 (https=) |
| RU (2) | RU2021128024A (https=) |
| WO (1) | WO2018219968A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201708655D0 (en) * | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| JP2023554489A (ja) * | 2020-12-22 | 2023-12-27 | ノバルティス アーゲー | 細胞培養中の分泌された組換え発現タンパク質中のシステイン残基の酸化レベルを低減するための方法 |
| GB202105424D0 (en) * | 2021-04-16 | 2021-06-02 | UCB Biopharma SRL | Cell culture processes |
| WO2025262319A1 (en) | 2024-06-21 | 2025-12-26 | Boehringer Ingelheim International Gmbh | Modifying blue color formation in bioprocesses |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| EP1482031B1 (en) | 1996-08-30 | 2015-10-28 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
| JP5290489B2 (ja) | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
| ATE472597T2 (de) | 2003-05-15 | 2010-07-15 | Wyeth Llc | Kontrollierte glukosezufuhr für tierzellkultur |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| TWI374935B (en) | 2004-08-27 | 2012-10-21 | Pfizer Ireland Pharmaceuticals | Production of α-abeta |
| ES2538986T3 (es) * | 2006-11-08 | 2015-06-25 | Wyeth Llc | Medios diseñados racionalmente para un cultivo celular |
| US8030027B2 (en) * | 2008-04-29 | 2011-10-04 | St. Jude Children's Research Hospital | Method for enhancing recombinant antibody production |
| US8252557B2 (en) | 2008-10-28 | 2012-08-28 | Chugai Seiyaku Kabushiki Kaisha | Peptide-containing culture medium for culturing animal cell |
| US20110262965A1 (en) | 2010-04-23 | 2011-10-27 | Life Technologies Corporation | Cell culture medium comprising small peptides |
| SG185037A1 (en) | 2010-04-26 | 2012-11-29 | Novartis Ag | Improved cell culture medium |
| AU2011246502B2 (en) | 2010-04-26 | 2014-08-28 | Novartis Ag | Improved cell cultivation process |
| CN102653729B (zh) | 2011-03-04 | 2014-07-16 | 上海赛金生物医药有限公司 | 一种用于中国仓鼠卵巢细胞的培养基 |
| WO2012145682A1 (en) * | 2011-04-21 | 2012-10-26 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| JP6265970B2 (ja) * | 2012-03-26 | 2018-01-24 | サノフイ | 安定なＩｇＧ４に基づく結合剤の製剤 |
| WO2013158275A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
| US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
| EP2968544A4 (en) * | 2013-03-15 | 2016-10-12 | Hoffmann La Roche | CELL CULTURE MEDIA AND METHOD FOR PRODUCING ANTIBODY |
| BR112016027797A2 (pt) | 2014-06-18 | 2017-10-31 | Medimmune Llc | métodos e meios de cultura de células compreendendo n-acetilcisteína |
| WO2016108765A1 (en) | 2014-12-29 | 2016-07-07 | Wirojpaisi Wanlop | Engine combustion system oxygen efficiency enhancing device with raised electrical voltage and improved installation method |
| GB201508180D0 (en) * | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| US11220668B2 (en) * | 2016-04-28 | 2022-01-11 | Merck Patent Gmbh | Method for reducing the trisulfide level in proteins |
| GB201608323D0 (en) * | 2016-05-12 | 2016-06-29 | Ucb Biopharma Sprl | Pharmaceutical compositions |
| CN106222129A (zh) | 2016-07-29 | 2016-12-14 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
| WO2018018613A1 (zh) * | 2016-07-29 | 2018-02-01 | 广东东阳光药业有限公司 | 一种提高抗体纯度的细胞培养基和培养方法 |
| GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
-
2017
- 2017-05-31 GB GBGB1708655.4A patent/GB201708655D0/en not_active Ceased
-
2018
- 2018-05-29 KR KR1020247019609A patent/KR20240096888A/ko active Pending
- 2018-05-29 MX MX2019014140A patent/MX2019014140A/es unknown
- 2018-05-29 KR KR1020257034169A patent/KR20250156183A/ko active Pending
- 2018-05-29 EA EA201992828A patent/EA201992828A1/ru unknown
- 2018-05-29 US US16/615,419 patent/US12077796B2/en active Active
- 2018-05-29 CA CA3065661A patent/CA3065661A1/en active Pending
- 2018-05-29 RU RU2021128024A patent/RU2021128024A/ru unknown
- 2018-05-29 BR BR112019024390-9A patent/BR112019024390A2/pt unknown
- 2018-05-29 HU HUE18743683A patent/HUE066922T2/hu unknown
- 2018-05-29 AU AU2018276376A patent/AU2018276376C1/en active Active
- 2018-05-29 JP JP2019566198A patent/JP7460370B2/ja active Active
- 2018-05-29 EP EP24164969.8A patent/EP4397682A3/en active Pending
- 2018-05-29 PL PL18743683.7T patent/PL3630946T3/pl unknown
- 2018-05-29 ES ES18743683T patent/ES2978394T3/es active Active
- 2018-05-29 IL IL270880A patent/IL270880B2/en unknown
- 2018-05-29 HR HRP20240585TT patent/HRP20240585T1/hr unknown
- 2018-05-29 CN CN201880035870.9A patent/CN110741077B/zh active Active
- 2018-05-29 MY MYPI2019006875A patent/MY193535A/en unknown
- 2018-05-29 CN CN202411456463.9A patent/CN119326882A/zh active Pending
- 2018-05-29 EP EP18743683.7A patent/EP3630946B1/en not_active Revoked
- 2018-05-29 IL IL317828A patent/IL317828A/en unknown
- 2018-05-29 WO PCT/EP2018/064102 patent/WO2018219968A1/en not_active Ceased
- 2018-05-29 KR KR1020197038895A patent/KR20200012972A/ko not_active Ceased
- 2018-05-29 RU RU2019143742A patent/RU2758674C2/ru active
-
2019
- 2019-11-18 CO CONC2019/0012871A patent/CO2019012871A2/es unknown
- 2019-11-26 CL CL2019003459A patent/CL2019003459A1/es unknown
-
2021
- 2021-08-31 JP JP2021141016A patent/JP7560420B2/ja active Active
-
2022
- 2022-07-06 JP JP2022109106A patent/JP7406593B2/ja active Active
-
2024
- 2024-08-23 US US18/813,117 patent/US20250051824A1/en active Pending
- 2024-11-11 AU AU2024259881A patent/AU2024259881B2/en active Active
- 2024-11-15 US US18/948,600 patent/US20250066832A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240585T1 (hr) | Postupci uzgoja stanica | |
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| JP2022177090A5 (https=) | ||
| RU2012131671A (ru) | Способ полипептидной модификации для очистки полипептидных мультимеров | |
| HRP20231175T1 (hr) | Postupci kultiviranja stanica | |
| HRP20190932T1 (hr) | Molekule protutijela koje se vežu na il-17a i il-17f | |
| FI2155783T4 (fi) | Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni | |
| PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
| HRP20130883T4 (hr) | Međuvrsno specifična cd3-epsilon-vežuća domena | |
| HRP20191983T1 (hr) | Konstrukti protutijela za cdh19 i cd3 | |
| RU2016129274A (ru) | Канинизированные мышиные антитела к человеческому pd-1 | |
| HRP20240102T1 (hr) | Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena | |
| HRP20251020T1 (hr) | Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3 | |
| AR110659A1 (es) | Proteínas de unión a antígenos anti-neuropilin y método para su uso | |
| JP2020537520A5 (https=) | ||
| AR097651A1 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
| RU2010145063A (ru) | Новые антитела, используемые для лечения рака | |
| HRP20191277T1 (hr) | Anti-cd26 antitijela i njihove primjene | |
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| JP2021517459A5 (https=) | ||
| AU2025204857A1 (en) | Producing compositions comprising two or more antibodies | |
| JP2017507132A (ja) | 抗体プロセス | |
| RU2014110953A (ru) | Микроорганизмы, несущие опухолевый антиген | |
| JP2022103201A (ja) | 抗体可変領域の多様化を促進する方法 | |
| RU2016129198A (ru) | Новое антитело против adam 17 и его применения для лечения рака |